Gerard C. Mazzenga
Novartis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gerard C. Mazzenga.
Journal of Controlled Release | 1991
Gerard C. Mazzenga; Bret Berner
Abstract The use of selected salts of zwitterions of varying polarizability, size, hydrogen-bonding ability and lipophilicity as criteria to improve skin permeation of zwitterionic drugs is described. Prior to this study, it was not appreciated that salts of zwitterions have substantially reduced dipole moments compared to the free zwitterionic species. Consequently, it was demonstrated that typically for the salt form, the melting point decreased, the solubility in both polar and nonpolar media increased and the solubility in polyurethane membranes and in stratum comeum increased dramatically. To study this effect systematically, phenylalanine, baclofen and two diacid angiotensin converting enzyme inhibitors were selected as model zwitterionic compounds. Covalency was the key determinant in the counterion to optimize the increase in solubility of the salt. Rigidity of the zwitterion was related to the size of the enhancement.
Pharmaceutical Research | 1988
Bret Berner; Donald R. Wilson; Richard H. Guy; Gerard C. Mazzenga; Frank H. Clarke; Howard I. Maibach
The relationship between pKa and skin irritation in man is studied for a homologous series of benzoic acid derivatives, which permeate through human skin at comparable rates (15–88 µg/cm2/hr). Skin irritation and pKa are correlated for pKa ≤ 4. Laser Doppler velocimetric assessment of skin blood flow, color meter readings, erythema, edema, and the primary irritation index are all linearly correlated and related to pKa, erythema at 24 hr appears to be the most sensitive parameter to variation in pKa when pKa ≤ 4.
Toxicological Sciences | 1990
Bret Berner; Donald R. Wilson; Robert J. Steffens; Gerard C. Mazzenga; Robert S. Hinz; Richard H. Guy; Howard I. Maibach
For a series of bases, which penetrate through human skin in vitro at similar rates (0.056-0.49 microM/cm2/hr), penetrant pKa is shown to correlate with erythema, edema, and color meter readings. As estimates of irritation, erythema, edema, and redness measurements are highly linearly correlated. For the selected series, irritation becomes significant for bases with a pKa greater than 8. The irritation potential of acids with pKa less than or equal to 4 has been previously reported; pKa appears highly predictive of acute skin irritation for acids and bases in man.
Journal of Controlled Release | 1992
Bret Berner; Gerard C. Mazzenga; Paul M. Gargiulo; Robert J. Steffens
Abstract The permeation of nicotine through human epidermis in vitro, membranes, adhesives, an adhesive-membrane laminate, and the laminate with epidermis was measured. Skin irritation in rabbits was shown to depend on the driving force of nicotine in the donor phase. A transdermal nicotine system is described that provides substantial control of nicotine entry through skin by a rate-controlling membrane.
Journal of Toxicology-cutaneous and Ocular Toxicology | 1989
Bret Berner; Donald R. Wilson; Richard H. Guy; Gerard C. Mazzenga; Frank H. Clarke; Howard I. Maibach
AbstractThe relationship between pKa and skin irritation in humans was studied for a homologous series of benzoic acid derivatives with predicted permeation through human skin at comparable rates (15-90 μg/cm2/hr). Skin irritation and pKa are strongly correlated, and, for pKa ≤4, skin irritation rapidly increases. Laser Doppler velocimetric assessment of skin blood flow, color meter readings, erythema, edema, and the primary irritation index are all linearly correlated and related to pKa; erythema at 24 hr appears to be the most sensitive variable.
Journal of Pharmaceutical Sciences | 1989
Bret Berner; Gerard C. Mazzenga; John H. Otte; Robert J. Steffens; Rong-Hwei Juang; Charles D. Ebert
Archive | 1990
Bret Berner; Charles D. Ebert; Gerard C. Mazzenga; John H. Otte
Journal of Medicinal Chemistry | 1985
Joel Slade; James L. Stanton; Daniel Ben-David; Gerard C. Mazzenga
Journal of Pharmaceutical Sciences | 1989
Bret Berner; John H. Otte; Gerard C. Mazzenga; Robert J. Steffens; C. D. Ebert
Journal of Pharmaceutical Sciences | 1989
Bret Berner; Rong-Hwei Juang; Gerard C. Mazzenga